BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 7782424)

  • 1. Ultrasonographic appearance of polycystic ovaries is associated with exaggerated ovarian androgen and oestradiol responses to gonadotrophin-releasing hormone agonist in women undergoing assisted reproduction treatment.
    Suikkari AM; MacLachlan V; Montalto J; Calderon I; Healy DL; McLachlan RI
    Hum Reprod; 1995 Mar; 10(3):513-9. PubMed ID: 7782424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Source localization of androgen excess in adolescent girls.
    Ibáñez L; Potau N; Zampolli M; Prat N; Gussinyé M; Saenger P; Vicens-Calvet E; Carrascosa A
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1778-84. PubMed ID: 7989484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pituitary-ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma.
    Fulghesu AM; Angioni S; Belosi C; Apa R; Selvaggi L; Ciampelli M; Iuculano A; Melis GB; Lanzone A
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):396-401. PubMed ID: 16918963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
    Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?
    Kaltsas GA; Korbonits M; Isidori AM; Webb JA; Trainer PJ; Monson JP; Besser GM; Grossman AB
    Clin Endocrinol (Oxf); 2000 Oct; 53(4):493-500. PubMed ID: 11012575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
    White D; Leigh A; Wilson C; Donaldson A; Franks S
    Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.
    Rosenfield RL; Barnes RB; Ehrmann DA
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1686-92. PubMed ID: 7989476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vivo ovarian androgen responses to recombinant FSH with and without recombinant LH in polycystic ovarian syndrome.
    Cheung AP; Pride SM; Yuen BH; Sy L
    Hum Reprod; 2002 Oct; 17(10):2540-7. PubMed ID: 12351525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary-ovarian responses to leuprolide acetate testing in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Ghizzoni L; Virdis R; Vottero A; Cappa M; Street ME; Zampolli M; Ibañez L; Bernasconi S
    J Clin Endocrinol Metab; 1996 Feb; 81(2):601-6. PubMed ID: 8636275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.
    Nestler JE; Jakubowicz DJ
    N Engl J Med; 1996 Aug; 335(9):617-23. PubMed ID: 8687515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome?
    Catteau-Jonard S; Bancquart J; Poncelet E; Lefebvre-Maunoury C; Robin G; Dewailly D
    Ultrasound Obstet Gynecol; 2012 Aug; 40(2):223-9. PubMed ID: 22648908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of functional ovarian hyperandrogenism in women with androgen excess.
    Ehrmann DA; Rosenfield RL; Barnes RB; Brigell DF; Sheikh Z
    N Engl J Med; 1992 Jul; 327(3):157-62. PubMed ID: 1319000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of hormonal response to the GnRH agonist leuprolide in brothers of women with polycystic ovary syndrome: a pilot study.
    Petermann TS; Cartes A; Maliqueo M; Vantman D; Gutiérrez C; Toloza H; Echiburú B; Recabarren SE
    Hum Reprod; 2004 Dec; 19(12):2742-7. PubMed ID: 15358722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
    Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
    J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian morphology as a predictor of hormonal values in polycystic ovary syndrome.
    van der Westhuizen S; van der Spuy ZM
    Ultrasound Obstet Gynecol; 1996 May; 7(5):335-41. PubMed ID: 8774098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrinological environment with regard to the number of microcysts in patients with polycystic ovary syndrome.
    Yoshino K; Takahashi K; Eda Y; Okada S; Kitao M
    Hum Reprod; 1992 Oct; 7(9):1201-4. PubMed ID: 1478997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population.
    Mortensen M; Ehrmann DA; Littlejohn E; Rosenfield RL
    J Clin Endocrinol Metab; 2009 May; 94(5):1579-86. PubMed ID: 19240158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
    Gonzalez F; Hatala DA; Speroff L
    Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between 17-hydroxyprogesterone responses to human chorionic gonadotropin and markers of ovarian follicle morphology in women with polycystic ovary syndrome.
    Maas KH; Chuan SS; Cook-Andersen H; Su HI; Duleba A; Chang RJ
    J Clin Endocrinol Metab; 2015 Jan; 100(1):293-300. PubMed ID: 25313914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.